NeOnc Technologies Holdings is trading 5.39% up now at $4.94 after opening-market gains on August 25, 2026, with biotech-sector momentum the clearest explanation.

  • Biotech ETF XBI was up 2.06% during regular trading.
  • No new company-specific announcement or filing was identified that directly explains the move.
  • The latest major catalyst was positive Phase 2a NEO100 data released August 12, including 48.9% six-month progression-free survival; broadly positive market tone may also have contributed, but company-specific causation remains unconfirmed.